BioVie Highlights Encouraging NE3107 Data In Parkinson's, Alzheimer's Trials
BioVie Inc (NASDAQ: BIVI) announced results from two Phase 2 trials assessing NE3107's potential in Parkinson's Disease (PD) and Alzheimer's Disease (AD).
Parkinson's patients treated with the combination of NE3107 and levodopa improved their UPDRS Part 3 (motor) score, which is 3+ points superior to those treated with levodopa alone.
Patients younger than 70 years old treated with NE3107 and levodopa experienced improvements that are roughly 6 points better than levodopa-treated alone. Patients younger than 70 years old represented roughly one-half of the study participants.
Related: This Small Biotech Company Touts Promising Data For Alzheimer's Candidate.
After 28 days of treatment, 63.6% of patients treated with levodopa alone experienced >30% improvement from Day 0 at the two-hour mark compared to 80% for NE3107+levodopa-treated patients and 88.9% of NE3107+levodopa patients under 70 years old.
There were no drug-related adverse events.
Full details from this trial will be presented at the upcoming Conference next year.
The company also shared additional data from Alzheimer's trial, demonstrating enhanced cognition after three months of treatment with NE3107 compared to baseline.
Patients showed improvement in daily function and reduced inflammation, with 18 of 22 patients with abnormal baseline scans showing improvement in one or more brain regions.
Price Action: BIVI shares are up 16.10% at $6.05 during the premarket session on the last check Tuesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
